
    combination slow recruitment, short shelf life for placebo and insufficient funding for further
    drug production (probably anyway sufficient number included).
  
['eosinophilic esophagitis']
['mometasone furoate', 'placebo']

        Inclusion Criteria:

          -  Age over 18 years

          -  Newly diagnosed cases with diagnostic criteria for EoE (ie at least 15 eosinophils per
             high power field (Magnification 10 times 40 = x400) in any field of view in any
             esophageal biopsy and concurrent symptoms of esophageal dysfunction mainly dysphagia.

          -  Women of childbearing age may participate provided that the pregnancy is not planned ,
             and that contraceptive use during therapy. The investigator will arrange a free
             pregnancy test must be performed within 1 week before treatment and be negative.

          -  Participation requires oral and written informed and signed consent form (see patient
             information and consent forms).

        Exclusion Criteria:

          -  Local infection of the pharynx or esophagus , such as fungal, bacterial or viral
             infection

          -  Active or latent tuberculosis in respiratory tract

          -  Recent history of major trauma or major surgery

          -  Recent significant infection or other physical stress

          -  Signs or suspicion of dehydration

          -  History of injury, illness or surgery in the adrenals or pituitary

          -  Pharynx or esophagussurgery or other trauma in the esophagus (incl. foreign body with
             a sharp object ) where healing has not taken place. (in case of doubt to be assessed
             by esophago - gastroscopy.

          -  Planned elective surgery during treatment

          -  Pregnancy, ongoing or planned

          -  Women of childbearing potential not using preventives during the study period

          -  Glaucoma

          -  Hypersensitivity to any component in the treatments

          -  Systemic or local steroid treatment last 4 months

          -  Contraindication to steroid therapy ( immune deficiency or suppression , stomach
             ulcers, diabetes)

          -  Medications that affect oesophageal motility (cisapride, erythromycin ) during the
             treatment period .

          -  PPIs during or up to 2 weeks before the treatment period

          -  Other cause of dysphagia (cancer, connective tissue disease , neurological disease )

          -  Volunteer who can not consent to the study or complete a questionnaire
      